Drug Type Biosimilar, Monoclonal antibody |
Synonyms Dupilumab Biosimilar (Mabpharm Ltd.), dupilumab-CMAB016, 度普利尤单抗生物类似药(迈博药业有限公司) + [2] |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Preclinical | China | 01 Aug 2023 | |
| Chronic rhinosinusitis with nasal polyps | Preclinical | China | 01 Aug 2023 | |
| Dermatitis, Atopic | Preclinical | China | 01 Aug 2023 | |
| Eosinophilic Esophagitis | Preclinical | China | 01 Aug 2023 | |
| prurigo nodularis | Preclinical | China | 01 Aug 2023 |






